Is Sclerostin Glycoprotein a Suitable Biomarker for Equine Osteochondrosis?

This research investigates the potential use of sclerostin glycoprotein as a biomarker for equine osteochondrosis, a bone disease. Despite finding some relation with the disease, it concluded that circulating levels of sclerostin glycoprotein are not suitable for use as a biomarker due to their lack of significance in disease progression and recovery.

Objective and Methodology

• The research aimed to investigate the relevance of sclerostin glycoprotein in the pathogenesis of equine osteochondrosis.
• The study examined the blood concentration of sclerostin glycoprotein in relation to the evolution of the disease, the environment, and age.
• The study used regression analysis to establish relationships between age and sclerostin concentrations. Two subgroups were considered: OC affected and healthy.

Results of the Research

• The study indicated a relationship between age and sclerostin concentrations.
• This relationship was significant in two observed subgroups: horses affected by osteochondrosis and healthy horses.
• However, when the study assessed the progression of the disease in relation to the concentration of sclerostin, the results were not significant.

Conclusion and Further Research

• Despite a link between sclerostin and osteochondrosis through the Wnt signaling pathway, the study suggests that the glycoprotein’s circulating levels cannot be used as a disease biomarker.
• The research concludes that more studies are needed to understand sclerostin’s functions in horses, as the glycoprotein may play a crucial role in bone homeostasis.